Takeda prices medicines to fulfill our purpose: Better health for people, brighter future for the world, aiming to make our highly innovative and life-transformative medicines available as soon as practically possible.
The Takeda Pricing Principle is centered around the goal of “optimal patient access,” which encompasses speed of access and breadth of coverage at a price that leads to long-term business sustainability. Together with our Access to Medicines strategy, this philosophy ensures we’re enabling sustainable access to our medicines to as many patients as possible.
Our main approaches are:
In 2019, we expanded our value assessments to consider the broad set of benefits that our treatments provide. In addition, we adapted and expanded our cost-effective approaches to capture this full value. We also expanded our value-based pricing model to Europe, specifically for Alofisel, our treatment for Crohn’s disease, becoming the first Japanese pharmaceutical company to only charge patients whose conditions have improved.
Ensuring patients have access to the medicines they need is a top priority for Takeda and, when setting prices, we aim to make our medicines accessible to as many patients as possible, while recognizing the value they bring to patients, providers and the health care system. In 2020, a small number of medicines received single-digit price increases, including a few plasma-derived specialty products that require significant resources to produce and make available for patients.
We recognize some patients face real challenges in affording their medicines, and that for some, this has been heightened during the COVID-19 pandemic. We continue to offer PAPs to assist eligible patients to access our medicines.
Takeda PAPs increase access to treatment, while maximizing medical benefits and standards of care by enabling patients to complete their prescribed course of treatment even if they can’t afford to pay for it in full. Our PAPs are designed to make sure there’s no disruption in treatment, which is critical, especially for cancer, to minimize the chance of the condition recurring.
These programs are designed around individual patients and use collaborative financing models in which patients share the cost of treatment according to what they can afford. And, together with our partners, we step in to cover the rest. In 2019, 23 PAPs for Adcetris, Entyvio, Ninlaro, Feiba and Immunine were running across 14 countries in Asia, Africa, Eastern Europe, Latin America and the Middle East. These programs have benefitted close to 1,600 patients with rare and complex diseases since program inception in 2016. We constantly look for opportunities to expand our PAPs with new programs launched every year in new disease areas.